Helsinn grants Stendhal rights to NEPA in several Latin America countries

2 February 2015

Family-run Swiss oncology specialist Helsinn has granted exclusive rights to Mexico-based Especificos Stendhal for NEPA, an oral fixed combination of netupitant and palonosetron developed for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Under the deal, financial terms of which were not disclosed, marketing and distribution rights have been granted to Stendhal for Mexico, Venezuela, Colombia, Peru, Ecuador and most of Central American countries.

NEPA is already approved in the USA with the trade name Akynzeo for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Japanese drugmaker Eisai (TYO; 4523) has marketing rights for the drug in the USA. NEPA is currently in the registration phase in Europe and will be soon submitted to other regulatory authorities in the territories included in the agreement between Helsinn and Stendhal, for the prevention of CINV.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK